Sales Growth of Generic APIs and In-House-Developed Formulations
First written in FY2016. 18 of 41 entries say "Advanced", first in FY2017-Q2. Latest entry: 2026-10-14.
0 other companies' latest entry also says "Other".
- FY2026AdvancedAnnual report
「As a result, consolidated net sales for the fiscal year were ¥50,650 million, essentially unchanged from the previous fiscal year. Although selling, general and administrative expenses increased due to higher payment processing fees, operating income rose 38.8% to ¥3,637 million, ordinary income rose 40.9% to ¥3,812 million, and net income attributable to owners of the parent rose 65.7% to ¥3,161 million, as cost of sales declined due to a substantial improvement in inventory write-downs and rigorous cost management through smart spending.」
Although net sales were nearly flat, operating income, ordinary income and net income attributable to owners of the parent increased substantially due to improved inventory write-downs and cost management. - FY2026-H1AdvancedAnnual report
「API sales declined 2.4% year on year to ¥11,304 million, as increased sales of antiallergic APIs were offset by lower sales of hemostatic and anticoagulant APIs. Formulation sales increased 6.4% to ¥13,736 million, as generic and over-the-counter products remained solid and sales of purchased generic drug products also increased. Health foods and other products posted sales of ¥100 million, up 7.2% year on year.」
API sales declined, while formulation sales and health foods and other products increased. Total sales were ¥25,141 million, up 2.3% year on year, reflecting updated business performance and segment composition. - FY2025Full-year results: higher API and formulation sales, lower health food sales and lower profitsAnnual report
「In APIs, the company began selling API products for formulations listed in the drug price schedule in December 2024, and sales of purchased products also remained solid, resulting in net sales of ¥22,872 million, up 5.7% year on year. In formulations, although contract manufacturing declined, mainly for long-listed products, sales of generic and over-the-counter drugs remained solid, resulting in net sales of ¥27,592 million, up 10.1% year on year. Health foods and other products remained in a difficult environment due to intensifying market competition and other factors, with net sales of ¥178 million, down 10.1% year on year.」
For the full year, API and formulation sales increased while health foods and other products posted lower sales. Operating income declined 32.7% year on year due to depreciation, product mix, write-downs on long-outstanding inventory and other factors. - FY2025-H1Higher API and formulation sales, lower health food sales and lower profitsAnnual report
「In API sales, the company began selling APIs for formulations listed in the drug price schedule in December 2024. Sales of APIs for generic drugs, including blood coagulation inhibitors, diabetes drugs, and antipyretic, analgesic and anti-inflammatory drugs, remained solid, resulting in net sales of ¥11,583 million, up 2.4% year on year. In formulation sales, although contract manufacturing declined, over-the-counter drugs performed strongly and generic drugs remained solid, resulting in net sales of ¥12,907 million, up 1.7% year on year. Health foods and other products remained in a difficult environment due to intensifying market competition and other factors, with net sales of ¥93 million, down 16.4% year on year. As a result, consolidated net sales for the interim period were ¥24,584 million, up 2.0% year on year. Although net sales increased, higher depreciation, the impact of inventory valuation and higher raw material costs due to higher raw material prices caused by the weaker yen resulted in operating income of ¥1,471 million, down 35.7% year on year, ordinary income of ¥1,470 million, down 36.5%, and interim net income attributable to owners of the parent of ¥908 million, down 41.5%.」
APIs and formulations posted higher sales, while health foods and other products posted lower sales. Consolidated net sales increased 2.0%, but operating income, ordinary income and interim net income attributable to owners of the parent declined due to higher depreciation, inventory valuation and raw material costs. - FY2024Full-year results: higher API sales, lower formulation sales and lower profitsAnnual report
「In APIs, production increases at the Seventh API Building, which began commercial production in January 2023, also contributed, and sales of APIs for generic drugs, including anti-inflammatory analgesic and antiplatelet drugs, remained strong. Net sales were ¥21,645 million, up 15.2% year on year. In formulations, although over-the-counter drug sales remained solid, net sales were ¥25,050 million, down 4.0% year on year due to lower generic drug sales. As a result, consolidated net sales for the fiscal year were ¥46,895 million, up 4.0% year on year. Although higher sales led to higher profits, higher raw material costs, mainly due to the weaker yen, and higher R&D expenses resulted in operating income of ¥3,894 million, down 25.2% year on year, ordinary income of ¥3,923 million, down 24.1%, and net income attributable to owners of the parent of ¥3,295 million, down 8.5%.」
API sales increased 15.2% year on year due to increased production at the Seventh API Building and other factors, while formulation sales declined 4.0%. Consolidated net sales increased, but operating income, ordinary income and net income declined due to higher raw material and R&D expenses. - FY2024-Q3Higher API sales, lower formulation sales and lower profits continueAnnual report
「In APIs, production increases at the Seventh API Building, which began commercial production in January 2023, also contributed, and sales of APIs for generic drugs, including anti-inflammatory analgesic and antiplatelet drugs, remained strong. Net sales were ¥16,373 million, up 15.8% year on year. In formulations, although over-the-counter drug sales remained solid, net sales were ¥18,138 million, down 10.5% year on year due to lower sales of generic drugs. Health foods and other products remained in a difficult environment due to intensifying market competition and other factors, with net sales of ¥151 million, down 9.0% year on year. As a result, consolidated net sales for the first nine months were ¥34,662 million, up 0.3% year on year. Although net sales were nearly flat, higher raw material costs, mainly due to the weaker yen, and higher R&D expenses resulted in operating income of ¥3,105 million, down 24.4% year on year, ordinary income of ¥3,122 million, down 23.4%, and net income attributable to owners of the parent of ¥2,339 million, down 12.1%.」
API sales increased 15.8% year on year due to increased production at the Seventh API Building and other factors, while formulation sales declined 10.5% due to lower generic drug sales. Net sales increased only 0.3%, while operating income, ordinary income and net income attributable to owners of the parent all declined. - FY2024-Q2Higher API sales, lower formulation sales and lower profits continueAnnual report
「In APIs, production increases at the Seventh API Building, which began commercial production in January 2023, also contributed, and sales of APIs for generic drugs, including anti-inflammatory analgesic and antiplatelet drugs, remained strong. Net sales were ¥11,303 million, up 21.8% year on year. In formulations, although over-the-counter drug sales remained solid, net sales were ¥12,695 million, down 9.1% year on year due to lower sales of generic drugs. As a result, consolidated net sales for the first six months were ¥24,110 million, up 3.2% year on year. Although net sales increased, higher raw material costs, mainly due to the weaker yen, and higher R&D expenses resulted in operating income of ¥2,289 million, down 19.0% year on year, ordinary income of ¥2,314 million, down 15.9%, and net income attributable to owners of the parent of ¥1,552 million, down 11.9%.」
API sales increased 21.8% year on year due to increased production at the Seventh API Building and other factors, while formulation sales declined 9.1% due to lower generic drug sales. Although net sales increased 3.2%, operating income, ordinary income and net income attributable to owners of the parent all declined due to higher raw material and R&D expenses. - FY2024-Q1Higher API sales, lower formulation sales and lower profitsAnnual report
「In APIs, production increases at the Seventh API Building, which began commercial production in January 2023, also contributed, and sales of APIs for generic drugs, including anti-inflammatory analgesic and antiplatelet drugs, remained strong. Net sales were ¥5,670 million, up 25.0% year on year. In formulations, although over-the-counter drug sales remained solid, net sales were ¥6,456 million, down 13.3% year on year due to lower sales of generic drugs. Health foods and other products remained in a difficult environment due to intensifying market competition and other factors, with net sales of ¥50 million, down 15.7% year on year. As a result, consolidated net sales for the first quarter were ¥12,178 million, up 1.1% year on year. Although net sales increased, higher raw material costs due mainly to higher raw material prices caused by the weaker yen, as well as higher R&D expenses, resulted in operating income of ¥1,080 million, down 28.0% year on year, ordinary income of ¥1,092 million, down 26.0%, and net income attributable to owners of the parent of ¥683 million, down 27.7%.」
API sales increased 25.0% year on year, supported by increased production at the Seventh API Building, while formulation sales declined 13.3% due to lower generic drug sales. Although net sales increased 1.1%, operating income, ordinary income and net income attributable to owners of the parent all declined due to higher raw material and R&D expenses. - FY2023Full-year results: lower API sales, higher formulation sales and lower profitsAnnual report
「In APIs, performance remained difficult due to lower sales of some existing products and intensifying market competition. Although sales of some APIs for generic drugs, including APIs for antihypertensive and antiplatelet drugs, remained solid, net sales were ¥18,783 million, down 3.6% year on year. In formulations, sales of internally developed generic and over-the-counter drugs increased, and performance remained strong. Net sales were ¥26,097 million, up 10.1% year on year. As a result, consolidated net sales for the fiscal year were ¥45,101 million, up 3.8% year on year. Although higher sales led to higher profits, increases in raw material costs and electricity charges, mainly due to the weaker yen and higher energy resource prices, as well as higher depreciation and R&D expenses, resulted in operating income of ¥5,207 million, down 20.5% year on year, ordinary income of ¥5,169 million, down 23.2%, and net income attributable to owners of the parent of ¥3,600 million, down 22.9%.」
The pattern of lower API sales and higher formulation sales continued for the full year. Although consolidated net sales increased, operating income, ordinary income and net income attributable to owners of the parent declined. - FY2023-Q3RestatedAnnual report
「In APIs, performance remained difficult due to lower sales of some existing products and intensifying market competition. Although sales of some APIs for generic drugs, including APIs for antihypertensive and antiplatelet drugs, remained solid, net sales were ¥14,143 million, down 4.5% year on year. In formulations, sales of internally developed generic drugs, contract manufacturing for new drugs and long-listed products in prescription medicines, and over-the-counter drugs increased, and performance remained strong. Net sales were ¥20,260 million, up 9.1% year on year.」
API sales declined 4.5% year on year, while formulation sales increased 9.1%, continuing the pattern of lower API sales and higher formulation sales. - FY2023-Q2Lower API sales, higher formulation sales and lower profits continueAnnual report
「In APIs, performance remained difficult due to lower sales of some existing products and intensifying market competition. Although sales of some APIs for generic drugs, including APIs for antihypertensive and antiplatelet drugs, remained solid, net sales were ¥9,277 million, down 9.8% year on year. In formulations, sales of internally developed generic drugs, contract manufacturing for new drugs and long-listed products in prescription medicines, and over-the-counter drugs increased, and performance was strong. Net sales were ¥13,969 million, up 16.1% year on year. As a result, for the first six months of the current fiscal year, net sales were ¥23,367 million, up 4.0% year on year. Although higher sales led to higher profits, increases in raw material costs and electricity charges, mainly due to the weaker yen and higher energy resource prices, as well as higher depreciation and R&D expenses, resulted in operating income of ¥2,826 million, down 27.1% year on year, ordinary income of ¥2,752 million, down 30.9%, and net income attributable to owners of the parent of ¥1,762 million, down 36.5%.」
API sales declined 9.8% year on year, while formulation sales increased 16.1%, resulting in 4.0% growth in consolidated net sales. However, operating income, ordinary income and net income attributable to owners of the parent all declined due to higher raw material costs and electricity charges, depreciation and R&D expenses. - FY2023-Q1Lower API sales, higher formulation sales and lower profitsAnnual report
「In APIs, performance remained difficult due to lower sales of some existing products and intensifying market competition. Although sales of some APIs for generic drugs, including anti-inflammatory analgesic and antiplatelet drugs, remained solid, net sales were ¥4,535 million, down 16.4% year on year. In formulations, sales of internally developed generic drugs and contract manufacturing for new drugs and long-listed products in prescription medicines increased, and performance was strong. Net sales were ¥7,445 million, up 19.1% year on year. Health foods and other products remained in a difficult environment due to intensifying market competition and other factors, with net sales of ¥60 million, down 12.4% year on year.」
APIs and health foods and other products posted lower sales and remained in difficult conditions, while formulations posted higher sales due to increased sales of internally developed generic drugs and contract manufacturing. - FY2022AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for anti-inflammatory analgesic and antiallergic drugs, increased, as did contract manufacturing sales for APIs for long-listed products, and performance remained solid. Net sales were ¥19,481 million. In formulations, sales of internally developed generic drugs and highly potent formulations, as well as contract manufacturing for new drugs and long-listed products in prescription medicines, increased, and performance was strong. Net sales were ¥23,703 million.」
For the full year, API sales were ¥19,481 million and formulation sales were ¥23,703 million. The company reported increased sales of generic APIs, internally developed generic drugs, highly potent formulations and contract manufacturing. - FY2022-Q3RestatedAnnual report
「In APIs, although sales of some existing products declined, overall performance remained solid, and net sales were ¥14,808 million. In formulations, sales of internally developed generic drugs and highly potent formulations, as well as contract manufacturing for new drugs and long-listed products in prescription medicines, increased, and performance remained solid. Net sales were ¥18,569 million.」
Although sales of some existing API products declined, APIs overall were described as solid. Formulations, including internally developed generic drugs, highly potent formulations and contract manufacturing, were also described as solid on increased sales. Year-on-year comparisons were not provided due to the adoption of the revenue recognition accounting standard. - FY2022-Q2RestatedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for anti-inflammatory analgesic, antiplatelet and esophagitis treatment drugs, increased, and performance remained solid. Net sales were ¥10,284 million. In formulations, sales of internally developed generic drugs and highly potent formulations, as well as contract manufacturing for new drugs and long-listed products in prescription medicines, increased, and performance remained solid. Net sales were ¥12,028 million.」
The company continued to state that APIs for generic drugs, internally developed generic formulations, highly potent formulations and contract manufacturing remained solid on increased sales. - FY2022-Q1RestatedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for anti-inflammatory analgesic, esophagitis treatment and pain treatment drugs, increased, and performance remained solid. Net sales were ¥5,427 million. In formulations, sales of internally developed generic drugs and highly potent formulations, as well as contract manufacturing for new drugs and long-listed products in prescription medicines, increased, and performance remained solid. Net sales were ¥6,251 million.」
The company said that APIs for generic drugs, internally developed generic formulations, highly potent formulations and contract manufacturing remained solid on increased sales. Year-on-year sales comparisons were not provided due to the adoption of the revenue recognition accounting standard. - FY2021-Q3AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for anti-inflammatory analgesic, esophageal inflammation treatment and pain treatment drugs, increased, as did overseas API sales, and performance remained solid. Net sales were ¥20,048 million, up 8.3% year on year. In formulations, sales of internally developed generic drugs, contract manufacturing for new drugs and long-listed products in prescription medicines, and highly potent formulations increased, and performance remained strong. Net sales were ¥17,579 million, up 12.2% year on year.」
In addition to APIs for generic drugs, overseas API sales increased, resulting in 8.3% year-on-year growth in API sales. Formulation sales, including internally developed generics, contract manufacturing and highly potent formulations, also increased 12.2% year on year. - FY2021-Q2AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for antihypertensive, anti-inflammatory analgesic and antiallergic drugs, increased, and performance remained solid. Net sales were ¥13,788 million, up 6.2% year on year. In formulations, sales of internally developed generic drugs, contract manufacturing for new drugs and long-listed products in prescription medicines, and over-the-counter drugs increased, and performance remained strong. Net sales were ¥12,093 million, up 19.3% year on year. Health foods and other products remained solid, with net sales of ¥154 million, up 11.3% year on year.」
Sales increased year on year across APIs for generic drugs, formulations, and health foods and other products. API sales rose 6.2% and formulation sales rose 19.3%, while consolidated net sales also increased 12.0%. - FY2021-Q1AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for antihypertensive and anti-inflammatory analgesic drugs, increased, and performance remained solid. Net sales were ¥7,164 million, up 3.4% year on year. In formulations, sales of internally developed generic drugs, contract manufacturing for new drugs and long-listed products in prescription medicines, and over-the-counter drugs increased, and performance was strong. Net sales were ¥6,479 million, up 38.6% year on year. As a result, for the first quarter of the current fiscal year, consolidated net sales were ¥13,704 million, up 17.5% year on year, operating income was ¥1,947 million, up 43.5%, ordinary income was ¥1,965 million, up 41.1%, and net income attributable to owners of the parent was ¥1,321 million, up 43.6%.」
Both APIs for generic drugs and formulations posted higher sales, with formulation sales particularly strong at 38.6% growth year on year. Consolidated net sales, operating income, ordinary income and net income attributable to owners of the parent also increased year on year. - FY2020AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for antihypertensive and anti-inflammatory analgesic drugs, increased, as did sales of some purchased products, and performance remained strong. Net sales were ¥24,211 million, up 9.7% year on year. In formulations, sales of internally developed generic drugs and contract manufacturing for new drugs and long-listed products in prescription medicines increased, and performance remained strong. Net sales were ¥20,530 million, up 9.4% year on year.」
Both APIs and formulations posted higher sales. API sales increased 9.7% year on year and formulation sales increased 9.4%. Consolidated net sales also rose 9.4% to ¥44,991 million. - FY2020-Q3AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for antihypertensive and anti-inflammatory analgesic drugs, increased, as did sales of some purchased products, and performance remained strong. Net sales were ¥18,515 million, up 12.3% year on year. In formulations, sales of internally developed generic drugs, contract manufacturing for new drugs and long-listed products in prescription medicines, and over-the-counter drugs increased, and performance remained strong. Net sales were ¥15,669 million, up 14.4% year on year. As a result, for the first nine months of the current fiscal year, consolidated net sales were ¥34,373 million, up 13.1% year on year, operating income was ¥4,584 million, up 25.1%, ordinary income was ¥4,642 million, up 23.7%, and net income attributable to owners of the parent was ¥3,241 million, up 27.1%.」
Both APIs for generic drugs and formulations posted higher sales, while net sales, operating income, ordinary income and net income attributable to owners of the parent also increased year on year. - FY2020-Q2AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for antihypertensive and anti-inflammatory analgesic drugs, increased, as did sales of some purchased products, and performance remained strong. Net sales were ¥12,980 million, up 17.5% year on year. In formulations, sales of internally developed generic drugs and contract manufacturing for new drugs and long-listed products in prescription medicines increased, and performance remained strong. Net sales were ¥10,135 million, up 13.3% year on year. As a result, for the first six months of the current fiscal year, consolidated net sales were ¥23,254 million, up 15.4% year on year, operating income was ¥2,830 million, up 21.6%, ordinary income was ¥2,876 million, up 21.4%, and net income attributable to owners of the parent was ¥2,003 million, up 19.7%.」
Both APIs for generic drugs and formulations posted higher sales, while net sales, operating income, ordinary income and net income attributable to owners of the parent also increased year on year. - FY2020-Q1AdvancedAnnual report
「In APIs, sales of APIs for generic drugs, including APIs for antihypertensive and anti-inflammatory analgesic drugs, increased, as did sales of some purchased products. Net sales rose substantially to ¥6,926 million, up 29.7% year on year. In formulations, sales of contract manufacturing for new drugs and long-listed products in prescription medicines, as well as sales of internally developed generic and over-the-counter drugs, increased, and performance remained strong. Net sales were ¥4,673 million, up 8.1% year on year. As a result, for the first quarter of the current fiscal year, consolidated net sales were ¥11,658 million, up 19.7% year on year, operating income was ¥1,357 million, up 24.0%, ordinary income was ¥1,392 million, up 22.0%, and net income attributable to owners of the parent was ¥920 million, up 18.0%.」
Both APIs for generic drugs and formulations posted higher sales, while consolidated net sales, operating income, ordinary income and net income attributable to owners of the parent also increased year on year. - FY2019Formulations also firmingAnnual report
「In APIs, although sales of some purchased products declined, sales of APIs for generic drugs, including APIs for antihypertensive and anti-inflammatory analgesic drugs, increased and remained solid. Net sales were ¥22,075 million, up 5.9% year on year. In formulations, although sales of over-the-counter drugs declined, sales of internally developed generic drugs and contract manufacturing for new drugs and long-listed products in prescription medicines increased, and performance remained solid. Net sales were ¥18,758 million, up 0.3% year on year. Health foods and other products remained in a difficult environment due to intensifying market competition and other factors, with net sales of ¥300 million, down 6.2% year on year.」
API sales remained strong, and formulations, which had been considered difficult through the previous quarter, were described as solid for the full year due to increased sales of internally developed generic drugs and contract manufacturing. Meanwhile, health foods and other products continued to post lower sales and remain in a difficult environment. - FY2019-Q3Active pharmaceutical ingredients strong, formulations and health foods challengingAnnual report
「By product category, sales of active pharmaceutical ingredients remained firm as sales of active pharmaceutical ingredients for generic products, including active pharmaceutical ingredients for antihypertensive drugs and anti-inflammatory analgesics, increased, despite a decline in sales of some purchased products. In formulations, sales of internally developed generic pharmaceuticals remained firm, but sales of over-the-counter drugs and contract manufacturing of new drugs and long-listed products for prescription use declined, resulting in challenging performance. Health foods and other products remained challenging because of intensifying market competition and other factors.」
While sales of some purchased products declined, active pharmaceutical ingredients performed firmly on increased sales of active pharmaceutical ingredients for generic products. Internally developed generics remained firm in formulations, while sales of over-the-counter drugs and contract sales of new drugs and long-listed products declined; health foods and other products also remained challenging. - FY2019-Q2Declining sales alongside higher profitsAnnual report
「As a result, for the cumulative second quarter of the current fiscal year, sales of the Company's own products increased, but total net sales were limited to ¥20,145 million, down 1.5% year on year, because of a decline in sales of purchased products. However, as a result of efforts to improve productivity and other initiatives, operating income was ¥2,328 million, up 2.7% year on year; ordinary income was ¥2,369 million, up 2.8%; and profit attributable to owners of the parent for the quarter was ¥1,674 million, up 5.5%.」
While net sales decreased 1.5% year on year because of lower sales of purchased products, operating income, ordinary income and profit attributable to owners of the parent for the quarter all increased year on year as a result of efforts to improve productivity. - FY2019-Q1AdvancedAnnual report
「As a result, for the cumulative first quarter of the current fiscal year, net sales were ¥9,740 million, up 0.6% year on year; operating income was ¥1,094 million, up 17.4%; ordinary income was ¥1,141 million, up 17.2%; and profit attributable to owners of the parent for the quarter was ¥780 million, up 15.8%.」
In the first quarter, net sales increased 0.6% year on year, operating income increased 17.4%, ordinary income increased 17.2%, and profit attributable to owners of the parent for the quarter increased 15.8%. - FY2018AdvancedAnnual report
「Sales of some active pharmaceutical ingredients for generic products, including active pharmaceutical ingredients for peptic ulcer treatments and antihypertensive drugs, remained firm, but overall performance remained challenging because of the optimization of drug use in clinical settings, the emergence of authorized generics, particularly for major products, and intensifying market competition. Sales were ¥20,848 million, down 6.4% from the previous fiscal year. Formulations performed well, with increased sales of internally developed generic pharmaceuticals for prescription use, contract manufacturing of new drugs and newly long-listed products, and sales of over-the-counter drugs, resulting in sales of ¥18,706 million, up 21.7% from the previous fiscal year.」
For the full fiscal year, active pharmaceutical ingredient sales decreased 6.4% from the previous fiscal year, while formulation sales increased 21.7% on internally developed generics, contract manufacturing and other factors, confirming the divergence in performance between the businesses with supporting figures. - FY2018-Q3AdvancedAnnual report
「As a result, for the cumulative third quarter of the current fiscal year, net sales were ¥29,637 million, up 6.2% year on year; operating income was ¥3,185 million, up 3.6%; ordinary income was ¥3,245 million, up 6.7%; and profit attributable to owners of the parent for the quarter was ¥2,300 million, up 12.6%. By product category, sales of some active pharmaceutical ingredients for generic products, including active pharmaceutical ingredients for peptic ulcer treatments and antihypertensive drugs, remained firm, but overall performance remained challenging because of the impact of the optimization of drug use in clinical settings and the emergence of authorized generics, particularly for major products. In formulations, performance was strong, with increased sales of internally developed generic pharmaceuticals for prescription use, contract manufacturing of new drugs and newly long-listed products, and sales of over-the-counter drugs.」
Net sales, operating income, ordinary income and profit attributable to owners of the parent for the cumulative third quarter increased year on year. The disclosure states that overall active pharmaceutical ingredients remained challenging because of the emergence of authorized generics and other factors, while internally developed generic formulations, contract manufacturing and over-the-counter drugs performed well. - FY2018-Q2RestatedAnnual report
「By product category, sales of some active pharmaceutical ingredients for generic products, including active pharmaceutical ingredients for peptic ulcer treatments and antihypertensive drugs, remained firm, but overall performance remained challenging because of the impact of the optimization of drug use in clinical settings and the emergence of authorized generics, particularly for major products. In formulations, performance was strong, with increased sales of internally developed generic pharmaceuticals for prescription use, contract manufacturing of new drugs and newly long-listed products, and sales of over-the-counter drugs.」
The disclosure continues to describe divergent performance: overall active pharmaceutical ingredients remained challenging because of the optimization of drug use and the emergence of authorized generics, while internally developed generic formulations, contract manufacturing and over-the-counter drugs performed well on increased sales. - FY2018-Q1Diverging performance between active pharmaceutical ingredients and formulationsAnnual report
「Sales of some active pharmaceutical ingredients for generic products, including active pharmaceutical ingredients for peptic ulcer treatments and antihypertensive drugs, remained firm, but overall performance remained challenging because of the impact of the optimization of drug use in clinical settings and the emergence of authorized generics, particularly for major products. Formulations performed well, with increased sales of internally developed generic pharmaceuticals for prescription use, contract manufacturing of new drugs and long-listed products, and sales of over-the-counter drugs.」
While some generic active pharmaceutical ingredients remained firm, overall active pharmaceutical ingredient performance was challenging because of the optimization of drug use and the emergence of authorized generics. Internally developed generic formulations, contract manufacturing and over-the-counter drugs performed well on increased sales, indicating divergent performance by product category. - FY2017AdvancedAnnual report
「Sales of active pharmaceutical ingredients for generic products, including active pharmaceutical ingredients for peptic ulcer treatments and antihypertensive drugs, remained firm, resulting in sales of ¥22,263 million, up 2.7% from the previous fiscal year. In formulations, contract manufacturing of new drugs and long-listed products for prescription use and sales of over-the-counter drugs declined, but performance remained firm because sales of internally developed generic pharmaceuticals increased, resulting in sales of ¥15,372 million, up 7.2% from the previous fiscal year.」
Sales of active pharmaceutical ingredients for generic products and internally developed generic formulations increased, resulting in consolidated net sales of ¥37,984 million, up 4.4% from the previous fiscal year. - FY2017-Q3AdvancedAnnual report
「As a result, for the cumulative third quarter of the current fiscal year, net sales were ¥27,919 million, up 3.4% year on year; operating income was ¥3,076 million, up 11.9%; ordinary income was ¥3,042 million, up 6.4%; and profit attributable to owners of the parent for the quarter was ¥2,044 million, up 6.9%. In formulations, contract manufacturing of new drugs and long-listed products for prescription use and sales of over-the-counter drugs declined, but performance remained firm because sales of internally developed generic pharmaceuticals increased.」
Formulations remained firm on the back of increased sales of internally developed generic pharmaceuticals, and net sales, operating income, ordinary income and profit attributable to owners of the parent for the quarter all increased year on year. - FY2017-Q2AdvancedAnnual report
「As a result, for the cumulative second quarter of the current fiscal year, net sales were ¥19,219 million, up 4.9% year on year; operating income was ¥2,126 million, up 14.9%; ordinary income was ¥2,083 million, up 10.4%; and profit attributable to owners of the parent for the quarter was ¥1,424 million, up 12.3%. In formulations, contract manufacturing of new drugs and long-listed products for prescription use and sales of over-the-counter drugs declined, but performance remained firm because sales of internally developed generic pharmaceuticals increased.」
Formulations remained firm on the back of increased sales of internally developed generic formulations, while net sales, operating income and other measures increased year on year. - FY2017-Q1RestatedAnnual report
「Sales of active pharmaceutical ingredients for generic products, including active pharmaceutical ingredients for peptic ulcer treatments and antihypertensive drugs, remained firm. In formulations, sales of internally developed generic pharmaceuticals for prescription use increased, while contract manufacturing of new drugs and long-listed products was at the previous year's level and sales of over-the-counter drugs declined, resulting in a slight decrease in total formulation sales.」
The disclosure states that sales of active pharmaceutical ingredients for generic products remained firm and sales of internally developed generic formulations increased, while total formulation sales declined slightly. - FY2016First statedAnnual report
「This was attributable to firm sales of active pharmaceutical ingredients for generic products and internally developed generic pharmaceuticals.」
Current-period sales were ¥36,370 million, up 6.8% year on year. Active pharmaceutical ingredient sales were ¥21,687 million, and formulation sales were ¥14,341 million.